BrioHealth Technologies
同心医疗
BrioHealth Technologies is the US subsidiary of Suzhou Concentric Medical (同心医疗), the Chinese company behind the BrioVAD full maglev artificial heart system . Concentric Medical established BrioHealth Solutions to run its US clinical and commercial operations, and in 2025 the subsidiary announced that the BrioVAD system had completed the safety phase of the INNOVATE clinical trial and received FDA approval to proceed to confirmatory-stage studies . The parent company, which counts Gaorong Ventures among its investors, filed for a STAR Market IPO in December 2025 with the stated mission of taking China's full maglev artificial heart global . By May 2026, Concentric Medical had completed its 100th BrioVAD implantation .
AI-generated — may contain errors, please verify.
Coverage
Rong Report | HT Aero, Xiwang, Helixon and Others Close Major Funding Rounds; Moonshot AI and Momenta Release Leading Models
Major Funding + Leading Model + Mass Production
高榕创投·Rongbao | Biren Technology and Seyond list successfully in Hong Kong, Moonshot AI completes major funding round
A new chapter begins.
高榕创投·Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
高榕创投·Concentric Medical Raises Over $100 Million in Strategic Funding to Take China's Full Maglev Artificial Heart Global
Gaorong Ventures co-led the round.
高榕创投·Hongshan Healthcare Investing: 17 Years From the Sidelines to Center Stage
Going earlier and deeper has become a defining feature of Hongshan's healthcare investments.
暗涌Waves·
